TY - JOUR
T1 - Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells
AU - Furuyama, Kenichiro
AU - Chera, Simona
AU - van Gurp, Léon
AU - Oropeza, Daniel
AU - Ghila, Luiza
AU - Damond, Nicolas
AU - Vethe, Heidrun
AU - Paulo, Joao A.
AU - Joosten, Antoinette M.
AU - Berney, Thierry
AU - Bosco, Domenico
AU - Dorrell, Craig
AU - Grompe, Markus
AU - Ræder, Helge
AU - Roep, Bart O.
AU - Thorel, Fabrizio
AU - Herrera, Pedro L.
N1 - Funding Information:
Acknowledgements We are grateful to R. Stein for reading the manuscript, and constructive comments and suggestions. We thank C. Gysler for technical help, J.-P. Aubry-Lachainaye for FACS assistance, C. Delucinge-Vivier and M. Docquier for RNA-seq. We thank Q. Zhou for viral vectors, R. Millican and P. Cain for anti-GCGR antibody, and R. Nano and L. Piemonti for human donor samples. Human islets were provided through the JDRF award 31-2008-416 (ECIT Islet for Basic Research program) or the NIDDK-funded Integrated Islet Distribution Program (IIDP) at City of Hope, National Institutes of Health (NIH) Grant no. DK098085. This work was funded with grants from the Research Council of Norway (NFR 247577) and the Novo Nordisk Foundation (NNF15OC0015054) to S.C.; NIH/NIDDK grant DK098285 to J.A.P.; Bergen Forskningsstiftelse (BFS2014REK02) and the Western Norway Regional Health Authority (Bergen Stem Cell Consortium) and the Novo Nordisk Foundation (NNF17OC0027258) to H.R.; NIH/NIDDK (Human Islet Research Network, DK104209 and DK108132), the Juvenile Diabetes Research Foundation (SRA-2015-67-Q-R), the Fondation Privée des HUG – Confirm Award, the Fondation Aclon, and the Swiss National Science Foundation (NRP63 no. 406340-128056, no. 310030_152965 and the Bonus of Excellence grant no. 310030B_173319) to P.L.H.
Publisher Copyright:
© 2019, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2019/3/7
Y1 - 2019/3/7
N2 - Cell-identity switches, in which terminally differentiated cells are converted into different cell types when stressed, represent a widespread regenerative strategy in animals, yet they are poorly documented in mammals. In mice, some glucagon-producing pancreatic α-cells and somatostatin-producing δ-cells become insulin-expressing cells after the ablation of insulin-secreting β-cells, thus promoting diabetes recovery. Whether human islets also display this plasticity, especially in diabetic conditions, remains unknown. Here we show that islet non-β-cells, namely α-cells and pancreatic polypeptide (PPY)-producing γ-cells, obtained from deceased non-diabetic or diabetic human donors, can be lineage-traced and reprogrammed by the transcription factors PDX1 and MAFA to produce and secrete insulin in response to glucose. When transplanted into diabetic mice, converted human α-cells reverse diabetes and continue to produce insulin even after six months. Notably, insulin-producing α-cells maintain expression of α-cell markers, as seen by deep transcriptomic and proteomic characterization. These observations provide conceptual evidence and a molecular framework for a mechanistic understanding of in situ cell plasticity as a treatment for diabetes and other degenerative diseases.
AB - Cell-identity switches, in which terminally differentiated cells are converted into different cell types when stressed, represent a widespread regenerative strategy in animals, yet they are poorly documented in mammals. In mice, some glucagon-producing pancreatic α-cells and somatostatin-producing δ-cells become insulin-expressing cells after the ablation of insulin-secreting β-cells, thus promoting diabetes recovery. Whether human islets also display this plasticity, especially in diabetic conditions, remains unknown. Here we show that islet non-β-cells, namely α-cells and pancreatic polypeptide (PPY)-producing γ-cells, obtained from deceased non-diabetic or diabetic human donors, can be lineage-traced and reprogrammed by the transcription factors PDX1 and MAFA to produce and secrete insulin in response to glucose. When transplanted into diabetic mice, converted human α-cells reverse diabetes and continue to produce insulin even after six months. Notably, insulin-producing α-cells maintain expression of α-cell markers, as seen by deep transcriptomic and proteomic characterization. These observations provide conceptual evidence and a molecular framework for a mechanistic understanding of in situ cell plasticity as a treatment for diabetes and other degenerative diseases.
UR - http://www.scopus.com/inward/record.url?scp=85062639517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062639517&partnerID=8YFLogxK
U2 - 10.1038/s41586-019-0942-8
DO - 10.1038/s41586-019-0942-8
M3 - Article
C2 - 30760930
AN - SCOPUS:85062639517
SN - 0028-0836
VL - 567
SP - 43
EP - 48
JO - Nature
JF - Nature
IS - 7746
ER -